Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.

Simple item page
dc.contributor.author

Williams, Derek J

dc.contributor.author

Creech, C Buddy

dc.contributor.author

Walter, Emmanuel B

dc.contributor.author

Martin, Judith M

dc.contributor.author

Gerber, Jeffrey S

dc.contributor.author

Newland, Jason G

dc.contributor.author

Howard, Lee

dc.contributor.author

Hofto, Meghan E

dc.contributor.author

Staat, Mary A

dc.contributor.author

Oler, Randolph E

dc.contributor.author

Tuyishimire, Bonifride

dc.contributor.author

Conrad, Thomas M

dc.contributor.author

Lee, Marina S

dc.contributor.author

Ghazaryan, Varduhi

dc.contributor.author

Pettigrew, Melinda M

dc.contributor.author

Fowler, Vance G

dc.contributor.author

Chambers, Henry F

dc.contributor.author

Zaoutis, Theoklis E

dc.contributor.author

Evans, Scott

dc.contributor.author

Huskins, W Charles

dc.contributor.author

The DMID 14-0079 Study Team

dc.date.accessioned

2022-02-01T19:50:43Z

dc.date.available

2022-02-01T19:50:43Z

dc.date.issued

2022-01-18

dc.date.updated

2022-02-01T19:50:43Z

dc.description.abstract

Importance

Childhood community-acquired pneumonia (CAP) is usually treated with 10 days of antibiotics. Shorter courses may be effective with fewer adverse effects and decreased potential for antibiotic resistance.

Objective

To compare a short (5-day) vs standard (10-day) antibiotic treatment strategy for CAP in young children.

Design, setting, and participants

Randomized double-blind placebo-controlled clinical trial in outpatient clinic, urgent care, or emergency settings in 8 US cities. A total of 380 healthy children aged 6 to 71 months with nonsevere CAP demonstrating early clinical improvement were enrolled from December 2, 2016, to December 16, 2019. Data were analyzed from January to September 2020.

Intervention

On day 6 of their originally prescribed therapy, participants were randomized 1:1 to receive 5 days of matching placebo or 5 additional days of the same antibiotic.

Main outcomes and measures

The primary end point was the end-of-treatment response adjusted for duration of antibiotic risk (RADAR), a composite end point that ranks each child's clinical response, resolution of symptoms, and antibiotic-associated adverse effects in an ordinal desirability of outcome ranking (DOOR). Within each DOOR rank, participants were further ranked by the number of antibiotic days, assuming that shorter antibiotic durations were more desirable. Using RADAR, the probability of a more desirable outcome was estimated for the short- vs standard-course strategy. In a subset of children, throat swabs were collected between study days 19 and 25 to quantify antibiotic resistance genes in oropharyngeal flora.

Results

A total of 380 children (189 randomized to short course and 191 randomized to standard course) made up the study population. The mean (SD) age was 35.7 (17.2) months, and 194 participants (51%) were male. Of the included children, 8 were Asian, 99 were Black or African American, 234 were White, 32 were multiracial, and 7 were of unknown or unreported race; 33 were Hispanic or Latino, 344 were not Hispanic or Latino, and 3 were of unknown or unreported ethnicity. There were no differences between strategies in the DOOR or its individual components. Fewer than 10% of children in either strategy had an inadequate clinical response. The short-course strategy had a 69% (95% CI, 63-75) probability of a more desirable RADAR outcome compared with the standard-course strategy. A total of 171 children were included in the resistome analysis. The median (range) number of antibiotic resistance genes per prokaryotic cell (RGPC) was significantly lower in the short-course strategy compared with the standard-course strategy for total RGPC (1.17 [0.35-2.43] vs 1.33 [0.46-11.08]; P = .01) and β-lactamase RGPC (0.55 [0.18-1.24] vs 0.60 [0.21-2.45]; P = .03).

Conclusions and relevance

In this study, among children responding to initial treatment for outpatient CAP, a 5-day antibiotic strategy was superior to a 10-day strategy. The shortened approach resulted in similar clinical response and antibiotic-associated adverse effects, while reducing antibiotic exposure and resistance.

Trial registration

ClinicalTrials.gov Identifier: NCT02891915.
dc.identifier

2788071

dc.identifier.issn

2168-6203

dc.identifier.issn

2168-6211

dc.identifier.uri

https://hdl.handle.net/10161/24319

dc.language

eng

dc.publisher

American Medical Association (AMA)

dc.relation.ispartof

JAMA pediatrics

dc.relation.isversionof

10.1001/jamapediatrics.2021.5547

dc.subject

and The DMID 14-0079 Study Team

dc.title

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.

dc.type

Journal article

duke.contributor.orcid

Fowler, Vance G|0000-0002-8048-0897

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Molecular Genetics and Microbiology

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Duke Clinical Research Institute

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Williams jamapediatrics_SCOUT-CAP_2022_oi_210080_1642179122.8134.pdf
Size:
437.47 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Articles